Results 1 to 10 of about 24,516 (282)

Long‐term safety and efficacy of eculizumab in generalized myasthenia gravis [PDF]

Muscle and Nerve, 2019
Introduction: Eculizumab is effective and well tolerated in patients with antiacetylcholine receptor antibody-positive refractory generalized myasthenia gravis (gMG; REGAIN; NCT01997229). We report an interim analysis of an open-label extension of REGAIN,
Srikanth Muppidi, Kimiaki Utsugisawa, Michael Benatar   +2 more
exaly   +5 more sources

Prospective Multi-Institutional Study of Eculizumab to Treat High-Risk Stem Cell Transplant Associated TMA. [PDF]

Blood, 2023
High-risk, complement mediated, untreated transplant-associated thrombotic microangiopathy (hrTMA) has dismal outcomes due to multi-organ dysfunction (MODS).
S. Jodele, C. Dandoy, P. Aguayo-Hiraldo, A. Lane, Ashley Teusink‐Cross, Anthony Sabulski, Kana Mizuno, B. Laskin, J. L. Freedman, Stella M. Davies   +9 more
semanticscholar   +2 more sources

Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis : a subgroup analysis of the REGAIN open-label extension study [PDF]

, 2019
The terminal complement inhibitor eculizumab was shown to improve myasthenia gravis-related symptoms in the 26-week, phase 3, randomized, double-blind, placebo-controlled REGAIN study (NCT01997229).
De Bleecker, Jan, Fujita, KP, Imai, T, Murai, H, O'Brien, F, Okumura, M, Shiraishi, H, Study Group, REGAIN, Suzuki, H, Suzuki, Y, Utsugisawa, K, Uzawa, A, Wang, JJ   +12 more
core   +3 more sources

Real‐world experience with eculizumab and switching to ravulizumab for generalized myasthenia gravis

Annals of Clinical and Translational Neurology
Objective Eculizumab and ravulizumab are complement protein C5 inhibitors, showing efficacy and tolerability for patients with anti‐acetylcholine receptor‐positive (AChR+) generalized myasthenia gravis (gMG) in phase 3 clinical trials and subsequent ...
Daiki Tokuyasu, Shigeaki Suzuki, Akiyuki Uzawa, Yuriko Nagane, Masayuki Masuda, Shingo Konno, Tomoya Kubota, Makoto Samukawa, Takamichi Sugimoto, Kei Ishizuchi, Munenori Oyama, Manato Yasuda, Hiroyuki Akamine, Yosuke Onishi, Yasushi Suzuki, Naoki Kawaguchi, Naoya Minami, Takashi Kimura, Masanori P. Takahashi, Hiroyuki Murai, Kimiaki Utsugisawa   +20 more
doaj   +2 more sources

Long-term safety and effectiveness of eculizumab in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: a 2-year interim analysis of post-marketing surveillance in Japan

Therapeutic Advances in Neurological Disorders, 2023
Background: The terminal complement C5 inhibitor eculizumab is approved in Japan for relapse prevention in aquaporin-4 antibody-positive (AQP4+) neuromyelitis optica spectrum disorder (NMOSD) and is undergoing mandatory post-marketing surveillance (PMS ...
Ichiro Nakashima, Jin Nakahara, Hiroaki Yokote, Yasuhiro Manabe, Kazumi Okamura, Kou Hasegawa, Kazuo Fujihara   +6 more
doaj   +2 more sources

Eculizumab as a treatment for C3 glomerulopathy: a single-center retrospective study

BMC Nephrology, 2023
Background C3 Glomerulopathy (C3G) is a rare glomerular disease caused by dysregulation of the complement pathway. Based on its pathophysiology, treatment with the monoclonal antibody eculizumab targeting complement C5 may be a therapeutic option. Due to
Thomas Welte, Frederic Arnold, Lukas Westermann, Felix A. Rottmann, Martin J. Hug, Elke Neumann-Haefelin, Athina Ganner   +6 more
doaj   +2 more sources

Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study. [PDF]

Blood, 2019
Ravulizumab, a new complement component C5 inhibitor administered every 8 weeks, was noninferior to eculizumab administered every 2 weeks in complement-inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria (PNH).
A. Kulasekararaj, A. Hill, S. Rottinghaus, Saskia M C Langemeijer, R. Wells, F. González-Fernández, A. Gaya, J. W. Lee, E. Gutierrez, C. Piatek, J. Szer, A. Risitano, S. Nakao, Eric S. Bachman, L. Shafner, A. Damokosh, S. Ortiz, A. Röth, R. Peffault de Latour   +18 more
semanticscholar   +2 more sources

Eculizumab in Aquaporin-4–Positive Neuromyelitis Optica Spectrum Disorder

New England Journal of Medicine, 2019
BACKGROUND Neuromyelitis optica spectrum disorder (NMOSD) is a relapsing, autoimmune, inflammatory disorder that typically affects the optic nerves and spinal cord.
Sean J Pittock, Achim Berthele, Kazuo Fujihara   +2 more
exaly   +2 more sources

Monoclonal IgG4/2κ Deposition Following Eculizumab Therapy for Recurrent Atypical Hemolytic Uremic Syndrome in Kidney Transplantation [PDF]

Kidney Medicine, 2019
Eculizumab is an emerging therapy for atypical hemolytic uremic syndrome (aHUS). Early identification and treatment of recurrent aHUS after kidney transplantation requires a high clinical suspicion but results in improved graft function and patient ...
Priyamvada Singh, Hui Chen, Craig E. Gordon, Sandeep Ghai, J. Mark Sloan, Karen Quillen, Sara Moradi, Vipul Chitalia, Amitabh Gautam, Joel Henderson, Jean M. Francis   +10 more
doaj   +2 more sources

Eculizumab treatment alters the proteometabolome beyond the inhibition of complement

JCI Insight, 2023
Therapeutic strategies targeting complement have revolutionized the treatment of myasthenia gravis (MG). However, a deeper understanding of complement modulation in the human system is required to improve treatment responses and identify off-target ...
Christopher Nelke, Christina B. Schroeter, Frauke Stascheit, Niklas Huntemann, Marc Pawlitzki, Alice Willison, Saskia Räuber, Nico Melzer, Ute Distler, Stefan Tenzer, Kai Stühler, Andreas Roos, Andreas Meisel, Sven G. Meuth, Tobias Ruck   +14 more
doaj   +2 more sources